Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Impact
The implications of H5866 on state law are significant. By passing this bill, the legislative assembly is addressing the ongoing concerns surrounding prescription limits and the hurdles patients face in accessing necessary medications. The ability to dispense a larger supply may reduce the number of pharmacy visits for patients and streamline the management of their treatments. However, it also raises concerns about ensuring safe prescribing practices and monitoring potential misuse, as this could open the door to diversion if not regulated properly.
Summary
House Bill H5866 seeks to amend the Uniform Controlled Substances Act by increasing the maximum fill for non-opioid, non-narcotic controlled substances classified as schedule II. Specifically, it proposes that pharmacists may dispense a ninety-day supply of these substances at one time, an increase from the current restrictions which generally limit the supply. The bill is designed to facilitate patient treatment and care by allowing for larger fills of medications that do not fall under the opioid category, addressing the needs of individuals requiring these substances for chronic conditions without the burden of frequent refills.
Sentiment
The sentiment surrounding H5866 appears generally positive, especially among advocates for improved healthcare access. Supporters argue that the bill is a step forward in improving patient care by reducing unnecessary barriers to medication access. However, there remains a cautious perspective regarding potential consequences, particularly the safety implications of increased supply of controlled substances even when they are non-opioid and non-narcotic, thus sparking discussions on the need for robust monitoring mechanisms to prevent abuse.
Contention
Notably, there are points of contention regarding the balance between easing access to necessary medications and the potential risks associated with larger quantities being dispensed at once. Critics have raised concerns that permitting such dispensations might foster environments conducive to medication mishandling or diversion. The debate underscores the need for careful oversight and regulation to ensure that while patients benefit from increased access, public health and safety considerations are not compromised.
Requires the department of health to amend its rules and regulations that allow for DEA-registered pharmacies to transfer electronic prescriptions at a patient's request.
Requires the department of health to amend its rules and regulations that allow for DEA-registered pharmacies to transfer electronic prescriptions at a patient's request (21 CFR Part 1306
Requires the department of health to amend its rules and regulations that allow for DEA-registered pharmacies to transfer electronic prescriptions at a patient's request (21 CFR Part 1306
Requires the department of health to amend its rules and regulations that allow for DEA-registered pharmacies to transfer electronic prescriptions at a patient's request.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.
Revises sections of the uniform controlled substances act to remove specific opioid dosage requirements, revises the uniform controlled substances act in accordance with current standards of professional practice and would repeal chapter 37.4 of title 5.